


CLAIMS

1. A compound of formula (I)



or a pharmaceutically acceptable salt thereof, wherein:

- 5 R^1 is selected from the group consisting of
- (i) C_6 - C_{14} -aryl optionally substituted with 1-2 substituents independently selected from the group consisting of C_{1-6} -alkoxy, halogen, and a group
-
- ;
- (ii) 5- to 6-membered heteroaryl optionally substituted with 1-2 substituents independently selected from the group consisting of halogen, hydroxy, C_{1-6} -alkoxy, $-B(OH)_2$, 5- to 6-membered heteroaryl, C_{1-6} -alkyl, and amino; and
 - (iii) 5- to 14-membered heterocyclyl optionally substituted with 1-3 substituents independently selected from the group consisting of halogen, C_{1-6} -alkyl, and oxo;
- 10 R^2 is selected from the group consisting of
- (i) C_{1-6} -alkyl optionally substituted with 1-3 substituents independently selected from halogen;
 - (ii) C_{3-14} -cycloalkyl;
 - (iii) C_6 - C_{14} -aryl optionally substituted with 1-2 substituents independently selected from halogen;
 - (iv) 5- to 14-membered heteroaryl optionally substituted with 1-3 substituents independently selected from halogen, C_{1-6} -alkyl, halo- C_{1-6} -alkyl, and oxo; and
 - (v) 5- to 14-membered heteroaryloxy optionally substituted with 1-3 substituents independently selected from halogen, C_{1-6} -alkyl, halo- C_{1-6} -alkyl, and oxo; and
- 15
- 20
- 25

- 122 -

- (vi) 5- to 14-membered heterocyclyl optionally substituted with 1-3 substituents independently selected from halogen, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, and oxo;
- R^3 is selected from the group consisting of hydrogen, halogen, C₁₋₆-alkoxy, C₃₋₁₄-cycloalkyloxy, and hydroxy;
- R^4 is selected from the group consisting of hydrogen, halogen, C₁₋₆-alkyl, hydroxy-C₁₋₆-alkyl, C₁₋₆-alkoxycarbonyl, C₁₋₆-alkoxycarbonyl-NH-, hydroxy, amino, carboxy, C₁₋₆-alkyl-C(O)-NH-, C₂₋₆-alkenyl-C(O)-NH-, carboxy-NH-, oxo, C₃₋₁₄-cycloalkyl, and hydroxy-C₃₋₁₄-cycloalkyl;
- L is selected from the group consisting of a covalent bond and -CH=CH-;
- A is selected from the group consisting of C₆-C₁₄-aryl, 5- to 14-membered heteroaryl, and 5- to 14-membered heterocyclyl; and
- n is 1, 2, 3, or 4.
2. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 is selected from the group consisting of
- (i) C₆-C₁₄-aryl substituted with 1-2 substituents independently selected from the
-
- group consisting of C₁₋₆-alkoxy, halogen, and a group
- (ii) 5- to 6-membered heteroaryl optionally substituted with 1-2 substituents independently selected from the group consisting of halogen, hydroxy, C₁₋₆-alkoxy, -B(OH)₂, 5- to 6-membered heteroaryl, C₁₋₆-alkyl, and amino; and
- (iii) 5- to 14-membered heterocyclyl optionally substituted with 1-3 substituents independently selected from the group consisting of halogen, C₁₋₆-alkyl, and oxo.
3. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 is C₆-C₁₄-aryl substituted with 1-2 substituents independently selected from the group consisting of C₁₋₆-alkoxy, halogen, and a
-
- group
4. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 is phenyl substituted with 1-2 substituents independently

- 123 -

selected from the group consisting of chloro, fluoro, methoxy and a group



5. The compound of formula (I) according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R^2 is selected from the group consisting of
 - (i) C_{1-6} -alkyl optionally substituted with 1-3 substituents independently selected from halogen;
 - (ii) C_{3-14} -cycloalkyl;
 - (iii) C_6-C_{14} -aryl substituted with 1-2 substituents independently selected from halogen;
 - (iv) 5- to 14-membered heteroaryl substituted with halo- C_{1-6} -alkyl; and
 - (v) 5- to 14-membered heteroaryloxy substituted with halogen.
6. The compound of formula (I) according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R^2 is selected from the group consisting of
 - (i) halo- C_6-C_{14} -aryl; and
 - (ii) 5- to 14-membered heteroaryl substituted with halo- C_{1-6} -alkyl.
7. The compound of formula (I) according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R^2 is selected from the group consisting of
 - (i) chlorophenyl;
 - (ii) 3-chloro-4-fluoro-phenyl; and
 - (iii) pyridyl substituted with CF_3 .
8. The compound of formula (I) according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R^3 is hydrogen or hydroxy.
9. The compound of formula (I) according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R^3 is hydroxy.
10. The compound of formula (I) according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein R^4 is selected from the group

- 124 -

consisting of hydrogen, halogen, C₁₋₆-alkyl, hydroxy-C₁₋₆-alkyl, C₁₋₆-alkoxycarbonyl, C₁₋₆-alkoxycarbonyl-NH-, hydroxy and oxo.

11. The compound of formula (I) according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein R⁴ is selected from the group consisting of hydrogen, halogen, and hydroxy.
12. The compound of formula (I) according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein R⁴ is selected from the group consisting of hydrogen, fluoro, and hydroxy.
13. The compound of formula (I) according to any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein L is a covalent bond.
14. The compound of formula (I) according to any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, wherein A is selected from the group consisting of 5- to 14-membered heteroaryl and 5- to 14-membered heterocyclyl.
15. The compound of formula (I) according to any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, wherein A is selected from the group consisting of pyrazolyl and azetidiny.
16. The compound of formula (I) according to any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, wherein n is 1 or 2.
17. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:
 - R¹ is selected from the group consisting of
 - (i) C₆-C₁₄-aryl substituted with 1-2 substituents independently selected from the group consisting of C₁₋₆-alkoxy, halogen, and a group


$$(R^4)_n - \text{A} - L - \text{wavy line}$$
 - (ii) 5- to 6-membered heteroaryl substituted with 1-2 substituents independently selected from the group consisting of halogen, C₁₋₆-alkoxy, C₁₋₆-alkyl, and amino; and

- 125 -

- (iii) 5- to 14-membered heterocyclyl optionally substituted with 1-3 substituents independently selected from the group consisting of halogen, C₁₋₆-alkyl, and oxo;
- R² is selected from the group consisting of
- 5 (i) C₁₋₆-alkyl optionally substituted with 1-3 substituents independently selected from halogen;
- (ii) C₃₋₁₄-cycloalkyl;
- (iii) C₆-C₁₄-aryl substituted with 1-2 substituents independently selected from halogen; and
- 10 (iv) 5- to 14-membered heteroaryl substituted with halo-C₁₋₆-alkyl;
- R³ is hydrogen or hydroxy;
- R⁴ is selected from the group consisting of hydrogen, halogen, C₁₋₆-alkyl, C₁₋₆-alkoxycarbonyl, C₁₋₆-alkoxycarbonyl-NH-, hydroxy and oxo;
- L is selected from the group consisting of a covalent bond and -CH=CH-;
- 15 A is selected from the group consisting of C₆-C₁₄-aryl, 5- to 14-membered heteroaryl, and 5- to 14-membered heterocyclyl; and
- n is 1 or 2.

18. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:

- 20 R¹ is C₆-C₁₄-aryl substituted with 1-2 substituents independently selected from the



- group consisting of C₁₋₆-alkoxy, halogen, and a group
- R² is selected from the group consisting of
- (i) halo-C₆-C₁₄-aryl; and
- (ii) 5- to 14-membered heteroaryl substituted with halo-C₁₋₆-alkyl;
- 25 R³ is hydroxy;
- R⁴ is selected from the group consisting of hydrogen, halogen, and hydroxy;
- L is a covalent bond;
- A is selected from the group consisting of 5- to 14-membered heteroaryl, and 5- to 14-membered heterocyclyl; and
- 30 n is 1 or 2.

- 126 -

19. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:

R^1 is phenyl substituted with 1-2 substituents independently selected from the



group consisting of chloro, fluoro, methoxy, and a group

- 5 R^2 is selected from the group consisting of

- (i) chlorophenyl;
- (ii) 3-chloro-4-fluoro-phenyl; and
- (iii) pyridyl substituted with CF_3 ;

R^3 is hydroxy;

- 10 R^4 is selected from the group consisting of hydrogen, fluoro, and hydroxy;

L is a covalent bond;

A is selected from the group consisting of pyrazolyl and azetidiny; and

n is 1 or 2.

20. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is selected from the group consisting of:

[(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone;

[(7R,9aS)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone;

[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1H-pyrazol-5-yl)phenyl]methanone;

[(7R,9aS)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1H-pyrazol-5-yl)phenyl]methanone;

[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-fluoro-1H-pyrazol-4-yl)phenyl]methanone;

[(7R,9aS)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-fluoro-1H-pyrazol-4-yl)phenyl]methanone;

[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-6-methoxypyridin-3-yl)methanone;

30

- [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(6-amino-2-methylpyridin-3-yl)methanone;
- [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone;
- 5 [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone;
- 5-[(7R,9aS)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carbonyl]-6-chloro-1-methylpyridin-2-one;
- 5-[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carbonyl]-6-chloro-1-methylpyridin-2-one;
- 10 3-[3-[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carbonyl]-2-chlorophenyl]-1,3-oxazolidin-2-one;
- 1-[3-[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carbonyl]-2-chlorophenyl]imidazolidin-2-one;
- 15 [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(4-methyl-1H-pyrazol-3-yl)phenyl]methanone;
- [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(4-methyl-1H-pyrazol-5-yl)phenyl]methanone;
- [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[3-(4-methyl-1H-pyrazol-3-yl)phenyl]methanone;
- 20 [(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone;
- [(7S,9aS)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone;
- 25 [(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1H-pyrazol-5-yl)phenyl]methanone;
- [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-fluoro-3-morpholin-4-ylphenyl)methanone;
- tert-butyl 4-[3-[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carbonyl]-2-fluorophenyl]piperazine-1-carboxylate;
- 30 [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-fluoro-3-piperazin-1-ylphenyl)methanone;
- (2-chloro-3-methoxyphenyl)-[rac-(7R,9aS)-7-hydroxy-7-(2-methylpropyl)-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone;

- (2-chloro-3-methoxyphenyl)-[rac-(7R,9aS)-7-cyclopentyl-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone;
- (2-chloro-3-methoxyphenyl)-[rac-(7R,9aR)-7-hydroxy-7-(trifluoromethyl)-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone;
- 5 [(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-[2-bromo-3-[(Z)-2-phenylethenyl]phenyl]methanone;
- [(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-[2-bromo-3-[(E)-2-phenylethenyl]phenyl]methanone;
- tert-butylN-[4-[(E)-2-[3-[(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazine-2-carbonyl]-2-bromophenyl]ethenyl]phenyl]carbamate;
- 10 N-[4-[(E)-2-[3-[(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazine-2-carbonyl]-2-bromophenyl]ethenyl]phenyl]prop-2-enamide;
- 4-[(E)-2-[3-[(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazine-2-carbonyl]-2-bromo-phenyl]vinyl]-N-methyl-benzamide;
- 15 [(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone;
- [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-hydroxyphenyl)methanone;
- 20 4-(3-((7S,9aR)-7-(4-chlorophenyl)-7-hydroxyoctahydro-2H-pyrido[1,2-a]pyrazine-2-carbonyl)-2-fluorophenyl)piperazin-2-one;
- 4-[3-[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carbonyl]-2-chlorophenyl]piperazin-2-one;
- 25 [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(6-oxa-1-azaspiro[3.3]heptan-1-yl)phenyl]methanone;
- [(7S,9aS)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(difluoromethoxy)phenyl]methanone;
- 30 [(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(difluoromethoxy)phenyl]methanone;
- [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone;


- [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone;
- 5 [(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-fluorophenyl)methanone;
- [(7S,9aS)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-fluorophenyl)methanone;
- 10 [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3S)-3-hydroxypyrrolidin-1-yl]phenyl]methanone;
- [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3R)-3-hydroxypyrrolidin-1-yl]phenyl]methanone;
- 15 [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3R)-3-hydroxypyrrolidin-1-yl]phenyl]methanone;
- [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-hydroxy-3-methylazetidin-1-yl)phenyl]methanone;
- 20 [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3S)-3-hydroxypiperidin-1-yl]phenyl]methanone;
- [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3R)-3-hydroxypiperidin-1-yl]phenyl]methanone;
- 25 [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(4-hydroxypiperidin-1-yl)phenyl]methanone;
- [2-chloro-3-(3-hydroxy-3-methylpyrrolidin-1-yl)phenyl]-[rac-(7R,9aS)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone;
- 30 [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3S,4S)-3,4-dihydroxypyrrolidin-1-yl]phenyl]methanone;

- [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[3-fluoro-3-(hydroxymethyl)azetidin-1-yl]phenyl]methanone;
- 5 [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[3-(hydroxymethyl)azetidin-1-yl]phenyl]methanone;
- [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1H-pyrazol-3-yl)phenyl]methanone;
- 10 [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(1H-pyrazol-3-yl)phenyl]methanone;
- [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(1,2-thiazol-3-yl)phenyl]methanone;
- [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(4-fluoro-1H-pyrazol-5-yl)phenyl]methanone;
- 15 [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1,2,4-thiadiazol-3-yl)phenyl]methanone;
- [(7S,9aR)-7-(3,4-difluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone;
- 20 [(7R,9aS)-7-(3,4-difluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone;
- [(7S,9aR)-7-(3,4-difluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(1H-pyrazol-5-yl)phenyl]methanone;
- [(7S,9aR)-7-(3,4-difluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(4-fluoro-1H-pyrazol-5-yl)phenyl]methanone;
- 25 [(7S,9aR)-7-(3,4-difluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone;
- [(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(4-fluoro-1H-pyrazol-5-yl)phenyl]methanone;
- 30 [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2,3-dihydro-1H-indol-4-yl)methanone;
- [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[4-chloro-5-(1H-pyrazol-3-yl)pyridin-3-yl]methanone;

- [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1,2-thiazol-3-yl)phenyl]methanone;
 [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1,2-thiazol-4-yl)phenyl]methanone;
 5 [(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1,2-thiazol-3-yl)phenyl]methanone;
 [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[4-methyl-5-(1H-pyrazol-3-yl)pyridin-3-yl]methanone;
 (2-chloro-3-methoxyphenyl)-[rac-(7R,9aS)-7-hydroxy-7-[6-(trifluoromethyl)pyridin-3-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone; and
 10 (2-chloro-3-methoxyphenyl)-[rac-(7R,9aR)-7-hydroxy-7-[6-(trifluoromethyl)pyridin-3-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone.
21. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is selected from the group consisting of:
- 15 [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone;
 [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1H-pyrazol-5-yl)phenyl]methanone;
 20 [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-fluoro-1H-pyrazol-4-yl)phenyl]methanone;
 [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone;
 25 [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone;
 [(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone;
 [(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1H-pyrazol-5-yl)phenyl]methanone;
 30 [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone;

- 132 -

- [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3R)-3-hydroxypyrrolidin-1-yl]phenyl]methanone;
- [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3S,4S)-3,4-dihydroxypyrrolidin-1-yl]phenyl]methanone;
- [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1H-pyrazol-3-yl)phenyl]methanone;
- [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(1H-pyrazol-3-yl)phenyl]methanone;
- [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(4-fluoro-1H-pyrazol-5-yl)phenyl]methanone;
- [(7S,9aR)-7-(3,4-difluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-methoxyphenyl]methanone;
- [(7S,9aR)-7-(3,4-difluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(1H-pyrazol-5-yl)phenyl]methanone; and
- [(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(4-fluoro-1H-pyrazol-5-yl)phenyl]methanone.
22. A process of manufacturing the compounds of formula (I) according to any one of claims 1 to 21, or pharmaceutically acceptable salts thereof, comprising:
- a) reacting an amine **12** or **14**, wherein R² is as defined herein and R³ is hydroxy (**12**) or hydrogen (**14**)



25

with a carboxylic acid **15**, wherein R¹ is as defined herein



- 133 -

- in the presence of a coupling reagent and a base to afford said compound of formula (I) wherein R^3 is hydroxy or hydrogen; and optionally, provided R^3 is hydroxy;
- 5 b) alkylating the alcohol R^3 by treating it with a base followed by addition of a suitable electrophile to yield the corresponding compound of formula (I), wherein R^3 is alkoxy or cycloalkyloxy; or
- 10 c) transforming the alcohol R^3 into a halogen by reacting the compound of formula (I) wherein R^3 is hydroxy with (i) a halogenating reagent; or (ii) a sulfonylating reagent, followed by reacting the intermediate sulfonate ester with a halogenide; to yield the corresponding compound of formula (I), wherein R^3 is halogen.
23. A compound of formula (I) according to any one of claims 1 to 21, or a pharmaceutically acceptable salt thereof, when manufactured according to the process of claim 22.
- 15 24. The compound of formula (I) according to any one of claims 1 to 21 and 23, or a pharmaceutically acceptable salt thereof, wherein said compound of formula (I) has an IC_{50} for monoacylglycerol lipase below 10 μ M.
25. A compound of formula (I) according to any one of claims 1 to 21, 23 and 24, or a pharmaceutically acceptable salt thereof, for use as therapeutically active substance.
- 20 26. A pharmaceutical composition comprising a compound of formula (I) according to any one of claims 1 to 21, 23 and 24, or a pharmaceutically acceptable salt thereof, and a therapeutically inert carrier.
27. The use of a compound of formula (I) according to any one of claims 1 to 21, 23 and 24, or a pharmaceutically acceptable salt thereof, for the treatment or prophylaxis of
- 25 neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal.
28. The use of a compound of formula (I) according to any one of claims 1 to 21, 23 and 24, or a pharmaceutically acceptable salt thereof, for the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral
- 30 sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer,

- 134 -

neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain and/or spasticity associated with pain in a mammal.

29. A compound of formula (I) according to any one of claims 1 to 21, 23 and 24, or a pharmaceutically acceptable salt thereof, for use in the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal.
30. A compound of formula (I) according to any one of claims 1 to 21, 23 and 24, or a pharmaceutically acceptable salt thereof, for use in the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain and/or spasticity associated with pain in a mammal.
31. The use of a compound of formula (I) according to any one of claims 1 to 21, 23 and 24, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal.
32. The use of a compound of formula (I) according to any one of claims 1 to 21, 23 and 24, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain and/or spasticity associated with pain in a mammal.
33. A method for the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal, which method comprises administering an effective amount of a compound of formula (I) according to any one of claims 1 to 21, 23 and 24, or a pharmaceutically acceptable salt thereof, to the mammal.

- 135 -

34. A method for the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain and/or spasticity associated with pain
5 in a mammal, which method comprises administering an effective amount of a compound of formula (I) according to any one of claims 1 to 21, 23 and 24, or a pharmaceutically acceptable salt thereof, to the mammal.
35. The invention as described hereinbefore.